AstraZeneca bags another cancer drug deal, this time with Inovio

ReutersAstraZeneca bags another cancer drug deal, this time with InovioReutersInovio will get $27.5 million upfront and potential future payments of up to $700 million, depending on the success of its INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. AstraZeneca said on Monday ...AstraZeneca to Pay Inovio Up to $700 Million for Cancer DrugBloombergInovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and ...CNNMoneyAstraZeneca, Inovio strike deal to find HPV cancer vaccinePhilly.com (blog)all 37 news articles »

Share this post